OMIP-112: 42-Parameter (40-Color) Spectral Flow Cytometry Panel for Comprehensive Immunophenotyping of Human

Laurien A Waaijer1, Bram van Cranenbroek1, Hans J P M Koenen1

  • 1Department of Laboratory Medicine, Radboud University Medical Center, Nijmegen, the Netherlands.

Insights

This study presents a novel 42-parameter spectral flow cytometry panel for comprehensive human immune cell profiling from limited patient blood samples. The optimized panel identifies over 80 immune subsets, aiding disease research and therapy monitoring.

Area of Science:

  • Immunology
  • Biotechnology
  • Single-cell analysis

Background:

  • Understanding the human immune system is crucial for disease research.
  • Spectral flow cytometry (SFM) offers deep single-cell profiling capabilities.
  • High-dimensional data analysis in SFM presents significant challenges.

Purpose of the Study:

  • To develop and optimize a high-dimensional SFM panel for comprehensive immune cell profiling.
  • To enable detailed identification of innate and adaptive immune cell subsets.
  • To facilitate disease understanding and therapy response monitoring through immune profiling.

Main Methods:

  • Optimization of a 42-parameter SFM panel using peripheral whole blood.
  • Inclusion of 40 commercially available fluorochromes, one stacked fluorochrome, and an autofluorescent parameter.
  • Utilized co-stimulatory, checkpoint, activation, homing, and maturation markers for deeper phenotyping.

Main Results:

  • Successfully identified innate and adaptive immune cells, including neutrophils, T cells, B cells, NK cells, and ILCs.
  • Identified over 80 distinct immune cell subsets within a single measurement using FlowSOM and manual annotation.
  • The 42-parameter panel is the first optimized on peripheral whole blood and demonstrates superior complexity compared to existing 40-color panels.

Conclusions:

  • The developed high-dimensional SFM panel provides a powerful tool for detailed immune profiling.
  • This panel enables the identification of a broad spectrum of immune cell subsets from limited patient samples.
  • The optimized panel can be instrumental in advancing disease research and monitoring therapeutic interventions.